Oppenheimer and Truist Lift Wave Life Sciences Ltd. (WVE) Price Targets After Positive Trial

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Wave Life Sciences Ltd. tops our list for being one of the most promising stocks. 

TheFly reported on December  16 that Oppenheimer raised its price target on WVE to $32 from $24 while maintaining an Outperform rating, citing highly encouraging interim Phase 1 data for WVE‑007, an investigational siRNA therapy that showed meaningful reductions in visceral and total body fat alongside lean mass increases in the INLIGHT trial.

Truist Financial followed on December 15, boosting its price target to $50 from $36 and reaffirming a Buy rating, highlighting clinical durability and safety as key valuation drivers.

Wave Life Sciences Ltd. (NASDAQ:WVE)’s December 8 Phase 1 INLIGHT results for WVE‑007 demonstrated a 9.4% reduction in visceral fat and a 4.5% decrease in total body fat at three months after a single 240 mg dose, along with increased lean mass, differentiating it from many existing obesity therapies and supporting the broader opportunity in metabolic diseases.

Financially, WVE strengthened its balance sheet via an upsized ~$402.5 million public offering priced at $19 per share on December 9, providing runway into late 2028 to advance WVE‑007 and other RNA programs.

Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical‑stage genetic medicines company developing RNA‑targeting therapeutics for genetically defined diseases. Its proprietary PRISM platform designs stereopure oligonucleotides for RNA editing, splicing, RNA interference (RNAi), and antisense silencing to precisely modulate gene expression and protein production.

While we acknowledge the potential of WVE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.